Strengthening Priority Businesses and Creating New Businesses through Integration of Foundational Technologies

「具体的には、富士フイルムは、インドの現地化学メーカーに技術支援を行い、半導体向けに求められる高品質な原材料の調達から生産までをインドで行う半導体材料サプライチェーンの構築を目指すとしている。」

「In addition, the company plans to invest a total of ¥170 billion in capital expenditure and R&D as growth investment in its semiconductor materials business over the 3 years through March 2027.」

「In June 2024, the company integrated its Display Materials, Industrial Equipment and Fine Chemicals businesses and established the Advanced Functional Materials Division. In conjunction with this, it has reported the business as the AF Business. The AF Business will centralise its human resources and business assets, create synergies in adjacent fields, and strengthen and enhance its ability to develop markets by sharing the knowledge and expertise in core technologies and business-building capabilities held by each group across business and market axes.」

「To further accelerate growth in its contract development and manufacturing business for biopharmaceuticals, the company will make a large-scale investment of approximately ¥180 billion in the North American sites of FUJIFILM Diosynth Biotechnologies, the core company of its biopharmaceutical CDMO business, hereinafter referred to as FDB.」

「The amount spent on research and development activities by the Group during the cumulative second quarter was ¥78,421 million, up 2.5% year on year. There were no significant changes in the status of research and development activities during the cumulative second quarter.」

「The amount spent on research and development activities by the Group during the cumulative second quarter was ¥76,507 million, up 1.0% year on year. There were no significant changes in the status of research and development activities during the cumulative second quarter.」

「The amount spent on research and development activities by the Group during the cumulative first quarter was ¥37,573 million, up 1.1% year on year. There were no significant changes in the status of research and development activities during the cumulative first quarter.」

「FUJIFILM Corporation established the Advanced Functional Materials Strategic Headquarters on 1 October 2021 to further accelerate business growth in high-functional materials, including semiconductor and display materials. The headquarters is responsible for cross-business strategic functions in the high-functional materials field, promoting further collaboration among businesses, the formulation of common themes for technology development, optimisation of management resources, and M&A and alliances.」

「The Group's R&D expenses for the nine months ended the third quarter were ¥111,941 million, up 1.1% year on year. There were no material changes in its R&D activities during the nine months ended the third quarter.」

「There were no material changes in the Group's R&D activities during the nine months ended the third quarter.」

「The Group's R&D expenses for the six months ended the second quarter were ¥74,409 million, down 6.6% year on year. There were no material changes in its R&D activities during the six months ended the second quarter.」

「The Group's R&D expenses for the three months ended the first quarter were ¥36,399 million, down 6.6% year on year. There were no material changes in its R&D activities during the three months ended the first quarter.」

「For example, the company will combine the Fujifilm Group's image-processing technologies with Fuji Xerox Co., Ltd.'s language-processing technologies to develop innovative products and services, including their application to generating diagnostic reports in the medical field, and expand its businesses in growth areas.」

「The Group's R&D expenses for the six months ended the second quarter were ¥79,684 million, up 0.2% year on year. There were no material changes in its R&D activities during the six months ended the second quarter.」

「The Group's R&D expenses for the three months ended the first quarter were ¥38,967 million, down 2.9% year on year. There were no material changes in its R&D activities during the three months ended the first quarter.」

「In November 2018, FUJIFILM Corporation established the Business Development and Creation Division to accelerate the commercialization of new business themes whose direction had become clearer. In April 2019, it established the Bio Science & Engineering Research Institute to strengthen its engineering capabilities across the biotechnology and healthcare fields, enhance its advanced gene therapy R&D capabilities, and improve responsiveness and efficiency by centralizing clinical development.」

「The Group's R&D expenses for the three months ended the first quarter were ¥40,143 million, up 6.7% year on year. There were no material changes in its R&D activities during the three months ended the first quarter.」

「In March 2018, FUJIFILM Corporation established the Bio Science & Technology Development Center and the Precision Process Technology Center.」

「The Group's R&D expenses for the nine months ended the third quarter were ¥118,966 million, down 3.0% year on year. There were no material changes in its R&D activities during the nine months ended the third quarter.」

「The Group's R&D expenses for the six months ended the second quarter were ¥80,958 million, down 2.4% year on year. There were no material changes in its R&D activities during the six months ended the second quarter.」

「The Group's R&D expenses for the three months ended the first quarter were ¥39,769 million, down 3.3% year on year. There were no material changes in its R&D activities during the three months ended the first quarter.」

「While advancing R&D in priority business fields through product designs that integrate these foundational and core technologies, the company is also pursuing the creation of new businesses to drive future growth.」